Payment overview · 2025
General Payments
$342.71
16 reported records · 9 companies
Healthcare provider profile · identity verified
Justin Robert Cramer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SEDALIA, MO · NPI 1114969292
Verified facts
What the public records show
CMS Open Payments records show Justin Robert Cramer, M.D. received $342.71 in general payments during 2025 across 16 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $96.49 | 28.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.95 | 17.5% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $39.93 | 11.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.43 | 10.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.71 | 9.8% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.43 | 6.5% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $19.31 | 5.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $17.35 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.11 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.71 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $96.49 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.95 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $37.43 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $37.43 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $16.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 230 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 189 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 42 |
| Losartan Potassium | Losartan Potassium | 144 | 33 |
| Pregabalin | Pregabalin | 139 | 26 |
| Tramadol Hcl | Tramadol Hcl | 136 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 28 |
| Metformin Hcl | Metformin Hcl | 113 | 25 |
| Sertraline Hcl | Sertraline Hcl | 111 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 21 |
| Lisinopril | Lisinopril | 101 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 27 |
| Ozempic | Semaglutide | 99 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 22 |
| Carvedilol | Carvedilol | 74 | 16 |
| Farxiga | Dapagliflozin Propanediol | 74 | 12 |
| Trazodone Hcl | Trazodone Hcl | 68 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 14 |
| Simvastatin | Simvastatin | 66 | 15 |
| Gabapentin | Gabapentin | 63 | 17 |
| Celecoxib | Celecoxib | 61 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 12 |
| Montelukast Sodium | Montelukast Sodium | 56 | suppressed |
| Alprazolam | Alprazolam | 54 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 13 |
| Furosemide | Furosemide | 42 | 14 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 11 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Felodipine Er | Felodipine | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Prednisone | Prednisone | 20 | 13 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.71 · 16 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, APTIMA, CAPLYTA, COMIRNATY, ENFLONSIA, M-M-R II, NURTEC ODT, Omnipod, PREVNAR 20, TEZSPIRE, THINPREP 2000 PROCESSOR, TZIELD, VAXNEUVANCE, VIVITROL, VRAYLAR, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error